Kimer Med is a post-seed biotech start-up, located in Nelson, New Zealand, developing a new broad-spectrum antiviral drug. The compound, which we call VTose, is a derivative of DRACO, which was tested and found effective in vitro against 15 different viruses in 11 tissue types, and against Influenza H1N1 in mice.
We are raising capital to extend testing to SARS-CoV-2, and to work toward clinical trials. We also plan to test against HIV, Hepatitis B, and other human viruses, as well as viruses which affect animals. The FIP, FIV, and FeLV viruses infect many beloved pet cats, frequently with fatal results.